Toyama Kohtaro, Karasawa Masamitsu, Yamane Arito, Koiso Hiromi, Yokohama Akihiko, Uchiumi Hideki, Saitoh Takayuki, Handa Hiroshi, Sato Ken, Takagi Hitoshi, Miyawaki Shuichi, Murakami Hirokazu, Nojima Yoshihisa, Tsukamoto Norifumi
Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, 371-8511, Japan.
Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma, Japan.
Int J Hematol. 2009 May;89(4):517-522. doi: 10.1007/s12185-009-0280-y. Epub 2009 Mar 24.
Approximately one-half of the cases of Budd-Chiari syndrome (BCS) are caused by bcr/abl negative chronic myeloproliferative disorders (CMPDs). Furthermore, a mutation in the Janus kinase protein (JAK2-V617F) is detected in half of the patients with BCS. However, whether the JAK2 mutation is the primary event leading to CMPDs and BCS is controversial. We present a report concerning a young woman who suffered from BCS prior to the onset of CMPDs. Analysis of X-chromosome inactivation patterns in this patient, using the human androgen receptor gene demonstrated monoclonal haematopoiesis in her granulocytes. In contrast, she had a low burden of a JAK2-V617F mutation positive clone among granulocyte populations. These results suggest that the JAK2-V617F mutation occurs after the onset of monoclonal haematopoiesis; thus the V617F mutation of JAK2 may not be the primary event in the induction of BCS.
约一半的布加综合征(BCS)病例由bcr/abl阴性慢性骨髓增殖性疾病(CMPD)引起。此外,在一半的BCS患者中检测到Janus激酶蛋白(JAK2-V617F)突变。然而,JAK2突变是否是导致CMPD和BCS的主要事件仍存在争议。我们报告了一名年轻女性,她在CMPD发病前就患有BCS。利用人类雄激素受体基因对该患者的X染色体失活模式进行分析,结果显示其粒细胞存在单克隆造血。相比之下,她粒细胞群体中JAK2-V617F突变阳性克隆的负担较低。这些结果表明,JAK2-V617F突变发生在单克隆造血开始之后;因此,JAK2的V617F突变可能不是诱发BCS的主要事件。